Streetbeat News

Regulatory

AUVI

BCDA

INVO

KBNT

SKIN

THRX

U.S. stocks traded higher with the Dow Jones gaining around 400 points. The NASDAQ surged 2.03% and the S&P 500 rose 1.61%. U.S. annual inflation rate slowed to 3.2% in October, below market estimates. BioCardia, Inc. soared 243% after FDA approval for a clinical trial. INVO Bioscience and Theseus Pharmaceuticals also saw significant gains. The Beauty Health Company, Kubient, Inc., and Applied UV faced sharp declines after negative reports. Oil and gold prices increased, while European and Asian markets showed mixed results.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 2:50 pm

BEN

David Alderman, a Digital Assets Research Analyst at Franklin Templeton, discussed the potential impact of a Bitcoin ETF on the financial industry at Benzinga's 'Future of Digital Assets' event. He suggested that a Bitcoin ETF would reduce friction between money within Registered Investment Advisors (RIAs) and other financial institutions.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:40 pm

BABA

JD

NIO

PDD

Investor Kevin O'Leary advocates for banning Chinese companies from listing on U.S. stock markets until they comply with the same accounting and transparency rules as U.S. firms. This stance could impact over 250 Chinese companies listed in New York, including Alibaba, Pinduoduo, JD.com, and NIO. O'Leary calls for greater accounting transparency, a sentiment echoed by the SEC. Previously, five Chinese companies voluntarily delisted from NYSE. Despite his firm stance, O'Leary is optimistic about future cooperation with China, suggesting forceful diplomacy may be necessary.

Portfolio Pulse from Neil Dennis

November 14, 2023 | 2:21 pm

NTLA

Intellia Therapeutics' stock is trading higher following the announcement that its drug NTLA-2002 received orphan drug designation from the European Union, potentially benefiting from incentives like market exclusivity.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:10 pm

HTBI

HomeTrust Bancshares, Inc. (NASDAQ:HTBI) announced the retirement of Executive Chair Dana L. Stonestreet, effective after the Annual Meeting on November 13, 2023. Richard T. 'Stick' Williams, currently Vice Chair and Lead Director, will succeed him. Stonestreet has been with HomeTrust since 1989, leading its growth from $200 million to $4.7 billion in assets. Williams, a retired Duke Energy executive, joined the HomeTrust Board in 2016 and is recognized for his extensive business experience.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:01 pm

AIP

Arteris, Inc. (NASDAQ:AIP) announced that its Ncore cache coherent interconnect IP has been certified for ISO 26262 automotive functional safety standard by exida. This certification, which includes support for ASIL D, the highest safety integrity level, confirms the IP's compliance with stringent safety requirements for automotive systems, particularly for ADAS and autonomous driving applications. The certification simplifies the chip certification process for Arteris' customers, reinforcing the company's leadership in system IP for the automotive industry.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:56 pm

EVOK

Evoke Pharma, Inc. (NASDAQ:EVOK) announced the issuance of U.S. Patent No. 11,813,231 by the USPTO for 'Nasal Formulations of Metoclopramide', covering their FDA-approved nasal spray GIMOTI. This patent strengthens Evoke's intellectual property rights and supports the commercial value of GIMOTI, especially as GLP-1 agonist medications for diabetes reveal more cases of gastroparesis. GIMOTI is unique as a non-oral treatment for diabetic gastroparesis, a condition that affects the absorption of oral medications.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:53 pm

MSFT

VRNT

Verint (NASDAQ:VRNT), known as The Customer Engagement Company, announced that its Verint Financial Compliance solution has achieved co-sell ready status with Microsoft and is now listed in the Microsoft AppSource Marketplace for use on Azure. This development strengthens the partnership between Verint and Microsoft, building on a twelve-year relationship. The solution offers advanced compliance controls for financial institutions, aiming to reduce risk and increase regulatory compliance while lowering operating costs. It provides secure capture, archive, and analysis for communications and trade surveillance, with high transcription accuracy and AI-driven insights.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:50 pm

BCDA

INVO

THRX

Theseus Pharmaceuticals (THRX) is exploring strategic alternatives, causing its stock to surge by 53%. BioCardia (BCDA) announced FDA approval for its Phase 3 clinical trial of CardiAMP cell therapy for ischemic heart failure, leading to a 166% stock increase. INVO BioScience (INVO) reported a smaller-than-expected GAAP EPS loss of $0.70, beating estimates by $0.17, but missed revenue targets by $0.96M, with a total revenue of $0.97M, resulting in a 51% stock jump.

Portfolio Pulse from ryanfaloona@benzinga.com

November 14, 2023 | 1:41 pm